LeMaitre Vascular (NASDAQ:LMAT) Upgraded to "Buy" at Wall Street Zen
LeMaitre Vascular (NASDAQ:LMAT) received an upgrade from "hold" to "buy" by Wall Street Zen, contributing to a "Moderate Buy" consensus rating among analysts with a target price of $112.60. The company reported strong financial results, beating EPS estimates and showing an 11.1% increase in revenue year-over-year, alongside positive guidance for FY 2026. Despite these positive fundamentals, there has been significant insider selling, with executives and directors selling over 54,000 shares worth approximately $5.9 million in the last 90 days.
LeMaitre Vascular, Inc. $LMAT is Conestoga Capital Advisors LLC's 7th Largest Position
Conestoga Capital Advisors LLC increased its stake in LeMaitre Vascular (LMAT) by 3.6% in the first quarter, making it their 7th largest holding. LeMaitre Vascular reported strong quarterly earnings of $0.68 per share and an 11.1% increase in revenue. Despite mixed Wall Street views and recent insider share sales, the company maintains a "Moderate Buy" rating with an average price target of $112.60.
LeMaitre Vascular, Inc. Financial Disclosures & Filings
This page provides access to LeMaitre Vascular, Inc.'s financial disclosures and regulatory filings, including quarterly and annual earnings reports, 8-K forms, 10-Q and 10-K reports, and investor presentations. The documents span from 2021 through Q1 FY2026, offering insights into the company's performance, strategy, and dividend growth. Investors can use these resources to make informed decisions about the company's financial health and future outlook.
LMAT - Lemaitre Vascular Inc Latest SEC Filings
This article provides a detailed financial overview and recent SEC filing information for Lemaitre Vascular Inc (LMAT). It includes current stock performance metrics, key financial ratios, insider and institutional ownership data, and various performance indicators across different timeframes. The company's stock closed at $98.74, up 2.90% on July 1st.
LeMaitre Vascular, Inc. Financial Disclosures & Filings
This page provides access to LeMaitre Vascular, Inc.'s financial disclosures and regulatory filings, including quarterly and annual earnings reports and investor presentations. The documents cover a period from Q1 FY2020 to Q1 FY2026, offering insights into the company's financial performance, growth strategies, and dividend history. Investors can use these resources to inform their investment decisions regarding the company.
LeMaitre Vascular, Inc. $LMAT Shares Sold by SG Americas Securities LLC
SG Americas Securities LLC significantly reduced its stake in LeMaitre Vascular, Inc. by 51.3% in the first quarter, now holding 27,204 shares valued at $2.97 million. This comes as LeMaitre Vascular reported better-than-expected quarterly earnings and an 11.1% increase in revenue year-over-year. Despite some insider selling, the company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $112.60.
Price to book forward of LeMaitre Vascular, Inc. – NASDAQ:LMAT
The article focuses on the "Price to book forward" metric for LeMaitre Vascular, Inc., traded on NASDAQ under the symbol LMAT. It primarily presents the company's financial overview within the TradingView platform, noting that the market was closed at the time of access. The content is sparse, highlighting financial data and general information about the company's stock.
LeMaitre Vascular, Inc. Actuals & Estimates (NASDAQ:LMAT)
This article provides an overview of LeMaitre Vascular, Inc. (NASDAQ: LMAT) stock, including its current price, performance, and analyst forecasts. It also details financial information such as market capitalization, earnings, revenue, dividends, and employee count, alongside technical analysis ratings. The content is presented as a financial data and estimate exploration for investors.
Price to sales forward of LeMaitre Vascular, Inc. – NASDAQ:LMAT
This article provides financial information for LeMaitre Vascular, Inc. (NASDAQ: LMAT), specifically focusing on its forward price to sales ratio. It lists the company on the Nasdaq Stock Market and appears to be a stub or placeholder from TradingView, indicating that detailed financial data for this metric would typically be presented in this section.
LeMaitre Vascular, Inc. Actuals & Estimates (SWB:LHU)
This article provides actuals and estimates for LeMaitre Vascular, Inc. (SWB:LHU), including financial data, analyst forecasts, and common stock information. It details the company's past earnings, revenue, net income, dividends, and offers insights into its stock performance and future earnings reports. The piece also includes an overview of employee count and EBITDA figures.
LeMaitre Vascular Inc (LMAT) Institutional Confidence
LeMaitre Vascular Inc (LMAT) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional shareholding increased by 8.41% quarter-over-quarter, reaching 102.98%. The largest institutional holder is ETHSX with 270.06K shares.
LMAT Forecast — Price Target — Prediction for 2027
This article provides a forecast for LeMaitre Vascular, Inc. (LMAT) stock, including its current price, analyst ratings, and financial data. It details the company's price target, EPS, revenue, and dividend information, along with offering answers to frequently asked questions about LMAT's stock performance and market capitalization. The article also touches upon technical analysis and investment considerations for potential investors.
LeMaitre Vascular, Inc. Actuals & Estimates (TRADEGATE:LHU)
This article provides an overview of LeMaitre Vascular, Inc. (TRADEGATE:LHU) stock, including historical data, analyst forecasts, and financial performance. It covers details like price targets, earnings reports, revenue, net income, dividends, EBITDA, and employee numbers, along with frequently asked questions for potential investors.
LHU Forecast — Price Target — Prediction for 2027
This article provides an LHU stock forecast, indicating a one-year price target of 101.39 EUR based on analyst estimates, with a maximum forecast of 115.26 EUR and a minimum of 87.09 EUR. It also details the company's financial performance, including recent earnings, revenue, net income, and dividend information. LeMaitre Vascular, Inc. is expected to release its next earnings report on July 23, 2026.
Rockefeller Capital Management L.P. Sells 100,923 Shares of LeMaitre Vascular, Inc. $LMAT
Rockefeller Capital Management L.P. significantly reduced its stake in LeMaitre Vascular, Inc. by selling 100,923 shares, decreasing its holdings by 37.9% in the fourth quarter. Despite this, LeMaitre Vascular reported strong quarterly earnings, exceeding analyst expectations with $0.68 per share and an 11.1% increase in revenue. The company also announced a $0.25 quarterly dividend, and analysts maintain a "Moderate Buy" rating with a target price of $112.60.
Riverbridge Partners LLC Buys Shares of 105,599 LeMaitre Vascular, Inc. $LMAT
Riverbridge Partners LLC initiated a new position in LeMaitre Vascular, Inc., acquiring 105,599 shares valued at approximately $11.5 million in the first quarter of 2026. This investment makes Riverbridge Partners LLC one of several institutional investors increasing their stakes in the medical instruments supplier. LeMaitre Vascular recently reported strong first-quarter earnings, beating EPS estimates and raising its guidance for both Q2 and the full fiscal year 2026.
LeMaitre Vascular (NASDAQ:LMAT) Rating Lowered to Hold at Wall Street Zen
Wall Street Zen downgraded LeMaitre Vascular (NASDAQ:LMAT) from a "buy" to a "hold" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $112.60. The company recently exceeded earnings expectations with $0.68 EPS and an 11.1% increase in revenue year-over-year. Insider selling has been noted from directors and executives, while institutional investors maintain a significant 84.64% stake in LMAT.
LeMaitre Vascular Inc (LMAT) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for LeMaitre Vascular Inc (LMAT), highlighting its current earnings forecast score of 7.80, which ranks 120th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $108.00 for LMAT, with most recommending a "Buy" trend. The company's expected revenue for the next quarter is $71.47 million, and its EPS for the previous quarter was $2.55, significantly exceeding the market expectation of $0.69.
LeMaitre Vascular Inc (LMAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of LeMaitre Vascular Inc (LMAT), detailing its price momentum score, current trading range, and technical indicator readings. It highlights that LMAT's price momentum score is 6.67, trading between a resistance level of 99.82 and a support level of 87.44. The analysis concludes with a "Sell" signal based on moving averages and technical indicators, with 0 buy and 2 sell signals from indicators, and 0 buy and 6 sell signals from moving averages.
LeMaitre Vascular Inc (LMAT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for LeMaitre Vascular Inc (LMAT), focusing on its regional revenue contributions. As of a recent update, the United States accounted for 56.72% of its revenue, followed by Other countries, Germany, Canada, and the United Kingdom. The company has not yet disclosed relevant data for business segments or profit contribution.
(LMAT) Volatility Zones as Tactical Triggers
This article analyzes Lemaitre Vascular Inc. (NASDAQ: LMAT), highlighting weak near and mid-term sentiment but a strong long-term positive outlook. It identifies key support and resistance levels, offering three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis emphasizes an exceptional 42.2:1 risk-reward setup targeting a 12.0% gain.
Kennedy Capital Management LLC Has $20.11 Million Stock Position in LeMaitre Vascular, Inc. $LMAT
Kennedy Capital Management LLC increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 14.8% during the fourth quarter, now holding 247,907 shares valued at $20.1 million. Despite insider selling totaling 54,453 shares worth $5.9 million, analysts generally maintain a "Moderate Buy" rating with an average target price of $112.60. The company reported quarterly earnings and revenue that met or slightly exceeded expectations, and they recently announced a quarterly dividend of $0.25 per share.
LeMaitre Vascular declares $0.25 dividend
LeMaitre Vascular has declared a quarterly dividend of $0.25 per share.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $112.60, driven by positive analyst sentiment and solid Q1 earnings that surpassed estimates. Despite recent insider selling, the company reported strong financial performance with Q1 EPS of $0.68 and revenue up 11.1% year-over-year, and has issued optimistic FY 2026 EPS guidance. Institutional investors hold a significant portion of the company's stock, further highlighting its market presence.
LeMaitre Vascular declares $0.25 dividend
LeMaitre Vascular, Inc. (LMAT) has declared a quarterly cash dividend of $0.25 per share. This dividend is payable on August 29, 2024, to stockholders of record as of August 15, 2024. The announcement signifies a return to shareholders and indicates the company's financial health.
LeMaitre Vascular (NASDAQ:LMAT) Shares Cross Above 200 Day Moving Average - Time to Sell?
LeMaitre Vascular (NASDAQ:LMAT) shares recently crossed above their 200-day moving average, reaching $97.83 before settling at $92.34. The company maintains a "Moderate Buy" consensus rating with an average analyst price target of $112.60, following several analyst upgrades. Despite positive earnings and dividend announcements, there has been significant insider selling, while institutional investors continue to hold the majority of the stock.
LeMaitre (NASDAQ: LMAT) director gets dividend equivalent right awards
LeMaitre Vascular director John A. Roush reported five routine compensation-related transactions in the form of dividend equivalent rights on June 4, 2026. These rights are tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025, and are the economic equivalent of one share of LeMaitre common stock, vesting with their underlying equity awards. This Form 4 filing reflects no cash payments by Roush and no open-market purchases or sales of shares.
LeMaitre Vascular (LMAT) director receives dividend equivalent rights awards
LeMaitre Vascular director Joseph P. Pellegrino Jr. was granted several Dividend Equivalent Rights awards on June 4, 2026, tied to existing equity awards. These rights, which are the economic equivalent of one share of LeMaitre Vascular common stock, vest proportionately with their underlying restricted stock unit and performance share unit awards from prior grant dates. These transactions are considered routine compensation accruals, not open-market stock trades.
[Form 4] LEMAITRE VASCULAR INC Insider Trading Activity
This article details an insider trading activity for LEMAITRE VASCULAR INC (LMAT) as reported in a Form 4 filing. Director Martha Shadan received compensation-related awards of dividend equivalent rights tied to prior equity grants, acquiring five derivative positions on June 4, 2026. These rights are economically equivalent to one share of common stock each, with no exercise price, and will vest alongside the underlying restricted stock unit and performance share unit awards granted between 2023 and 2025.
LeMaitre Vascular (LMAT) director receives new dividend equivalent rights grants
LeMaitre Vascular director John James O’Connor was granted dividend equivalent rights on June 4, 2026, as routine compensation tied to existing restricted stock unit and performance share unit awards. These rights, each economically equivalent to one share of LMAT common stock, accrue at a price of $0.00 and vest proportionately with the underlying awards from 2023, 2024, and 2025. Following these transactions, O’Connor directly holds 5.0674 dividend equivalent rights, reflecting equity-based compensation rather than open-market trading.
LeMaitre Vascular (NASDAQ: LMAT) director gets dividend equivalent awards
LeMaitre Vascular director Lawrence J. Jasinski has received grants of dividend equivalent rights tied to his existing equity awards, specifically restricted stock unit and performance share unit awards from 2023, 2024, and 2025. These rights are compensation-related accruals and do not involve open-market buying or selling of shares. Each dividend equivalent right mirrors the economic value of one share of LeMaitre Vascular common stock and vests proportionally with the underlying awards.
LeMaitre Vascular (LMAT) awards dividend equivalent rights to executive
LeMaitre Vascular's Senior V.P. of Operations, Trent G. Kamke, was granted multiple dividend equivalent rights on June 4, 2026, as per a Form 4 filing. These rights, which are the economic equivalent of one share of common stock, accrued on previously awarded restricted stock and performance share units from 2022, 2023, 2024, and 2025. The transactions are considered compensation-related accruals and do not represent open-market purchases or sales.
Price-Driven Insight from (LMAT) for Rule-Based Strategy
This article provides a price-driven analysis for Lemaitre Vascular Inc. (LMAT) for rule-based trading strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, presenting an exceptional risk-reward setup. The analysis offers three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis generated by AI models.
LeMaitre Vascular (LMAT) holders approve directors, say-on-pay and 2026 auditor
LeMaitre Vascular, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved the election of two Class II directors, an advisory vote on executive compensation, and the ratification of Grant Thornton LLP as the independent registered public accounting firm for 2026. A total of 21,336,301 shares were represented, indicating high participation. All proposals received majority support based on votes cast.
LeMaitre Vascular (NASDAQ:LMAT) Receives Outperform Rating from Barrington Research
Barrington Research has reiterated its "Outperform" rating for LeMaitre Vascular (NASDAQ:LMAT), setting a price target of $120.00, suggesting a 29% upside. This follows the medical instruments supplier's strong quarterly earnings, which surpassed expectations with Q1 EPS of $0.68 and an 11.1% increase in revenue. The company also received several other positive analyst updates, contributing to a consensus "Moderate Buy" rating with an average target of $112.60.
LeMaitre Vascular (Nasdaq:LMAT) - Stock Analysis
This Simply Wall St analysis of LeMaitre Vascular (Nasdaq: LMAT) details the company's stock performance, financial health, growth prospects, and recent news. It highlights the company's strong past performance and dividends, despite some analyst concerns regarding insider selling and board refreshment, noting an updated analyst price target of US$118.75 and recent Q1 2026 revenue growth.
AlphaQuest LLC Grows Position in LeMaitre Vascular, Inc. $LMAT
AlphaQuest LLC significantly increased its stake in LeMaitre Vascular (NASDAQ:LMAT) by 155.4% in the fourth quarter, now owning 27,521 shares valued at $2.23 million. This comes despite recent insider selling, with insiders offloading 269,891 shares worth $28.97 million over the past 90 days. The company reported strong financial results, beating EPS estimates and raising guidance, and announced a quarterly dividend of $0.25 per share.
Thrivent Financial for Lutherans Grows Stock Holdings in LeMaitre Vascular, Inc. $LMAT
Thrivent Financial for Lutherans significantly increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 492.0% in the fourth quarter, now owning 88,950 shares valued at $7.21 million. The article also details other institutional investor activity, LeMaitre Vascular's financial performance, recent insider selling, and current analyst ratings, with the stock holding a "Moderate Buy" consensus.
LeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. Management will engage in a fireside chat at the Jefferies conference and provide a presentation at the Goldman Sachs event. The company specializes in devices and services for peripheral vascular disease.
LeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced its participation in two investor conferences in June 2026. Management will be engaging in a fireside chat at the Jefferies Global Healthcare Conference on June 3rd and presenting at the Goldman Sachs Annual Global Healthcare Conference on June 10th. LeMaitre is a provider of devices and services for peripheral vascular disease.
LeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two investor conferences in June. Management will attend the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference on June 10, 2026. The company specializes in devices for peripheral vascular disease.
LeMaitre schedules June talks at Jefferies and Goldman healthcare events
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that its management will participate in two investor conferences in June 2026. The company will attend the Jefferies Global Healthcare Conference in New York on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference in Miami Beach on June 10, 2026, delivering scheduled presentations at both events. LeMaitre, a provider of devices for peripheral vascular disease, aims to engage with investors and share company updates.
LeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced its participation in two investor conferences in June. Management will attend the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference on June 10, 2026, presenting at both events. The company provides devices, implants, and services for peripheral vascular disease treatment.
LeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced its participation in two investor conferences in June: the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference on June 10, 2026. Management will hold a fireside chat at the former and present at the latter. The company specializes in medical devices for peripheral vascular disease.
GSA Capital Partners LLP Has $1.72 Million Position in LeMaitre Vascular, Inc. $LMAT
GSA Capital Partners LLP significantly increased its stake in LeMaitre Vascular, Inc., now holding 21,234 shares valued at $1.72 million. This comes as other institutional investors have also adjusted their positions, and company insiders have recently sold shares. Analysts have a "Moderate Buy" consensus rating for LeMaitre Vascular, with a price target of $112.60.
Three Healthcare Stocks Facing Potential Headwinds in 2026
The article highlights three healthcare stocks - Envista Holdings, LeMaitre Vascular, and Brookdale Senior Living - that are expected to face challenges in 2026. The broader healthcare sector is experiencing uneven performance due to past COVID inventory offloading and increased competition from venture capital. These companies exhibit issues such as muted revenue growth, negative returns on capital, high forward P/E ratios, and flat or declining sales forecasts.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of "Moderate Buy" from Analysts
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $112.60. The company recently reported strong Q1 earnings, beating EPS expectations, and announced a quarterly dividend of $0.25 per share. Insider selling by directors Bridget A. Ross and David B. Roberts has also been noted.
Wakefield Asset Management LLLP Buys New Position in LeMaitre Vascular, Inc. $LMAT
Wakefield Asset Management LLLP has acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT), purchasing 13,933 shares valued at approximately $1.13 million. This comes as several hedge funds have adjusted their positions in the medical instruments supplier. Analysts currently rate LeMaitre Vascular as a "Moderate Buy" with an average price target of $112.60, following the company's Q1 earnings beat and 11.1% revenue growth year-over-year.
LeMaitre Vascular Senior Vice President of Operations Trent Kamke Sells 44% Of Holding
NULL
LeMaitre Vascular stock (US52567J1079): Q1 beat and raised 2026 guidance
LeMaitre Vascular reported strong Q1 2026 results with revenue up 11% to $66.55 million and net income of $15.68 million. The company raised its full-year 2026 sales guidance to $277-283 million and issued a quarterly dividend of $0.25 per share. Growth was driven by grafts, valvulotomes, and carotid shunts, with significant regional sales increases in EMEA and APAC.
